Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
US Stem Cell's Capital Expenditure for the
three
months ended in Dec. 2022 was $0.00 Mil. Its Revenue for the
three
months ended in Dec. 2022 was $0.02 Mil.
Hence, US Stem Cell's Capex-to-Revenue for the
three
months ended in Dec. 2022 was 0.00.
US Stem Cell Capex-to-Revenue Historical Data
The historical data trend for US Stem Cell's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of US Stem Cell's Capex-to-Revenue
For the Biotechnology subindustry, US Stem Cell's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell's Capex-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where US Stem Cell's Capex-to-Revenue falls into.
US Stem Cell Capex-to-Revenue Calculation
US Stem Cell's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
US Stem Cell (OTCPK:USRM) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
US Stem Cell Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of US Stem Cell's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
USRM has been successfully added to your 